Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. - sprookjes - yvandenbroek - TriplyDB

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

http://www.wikidata.org/entity/Q34499843

about

Generation of high-affinity DNA aptamers using an expanded genetic alphabet Aptamers in Therapeutics Selection and Biosensor Application of Aptamers for Small Molecules Advanced drug delivery and targeting technologies for the ocular diseases Modified Nucleoside Triphosphates for In-vitro Selection Techniques Ocular Complications of Diabetes and Therapeutic Approaches Methods for Improving Aptamer Binding Affinity From selection hits to clinical leads: progress in aptamer discovery Aptamers: A promising chemical antibody for cancer therapy Bioengineering of noncoding RNAs for research agents and therapeutics Corneal neovascularization and biological therapy Generation of Aptamers with an Expanded Chemical Repertoire Nucleic acid aptamers: research tools in disease diagnostics and therapeutics Biosafe nanoscale pharmaceutical adjuvant materials Waveguide-mode sensors as aptasensors Receptor tyrosine kinase-mediated angiogenesis Oligonucleotide Therapies: The Past and the Present Aptamers in diagnostics and treatment of viral infections miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy CS-SELEX Generates High-Affinity ssDNA Aptamers as Molecular Probes for Hepatitis C Virus Envelope Glycoprotein E2 A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1 Conformational plasticity of RNA for target recognition as revealed by the 2.15 A crystal structure of a human IgG-aptamer complex An Exocyclic Methylene Group Acts As a Bioisostere of the 2′-Oxygen Atom in LNA Synthesis, Improved Antisense Activity and Structural Rationale for the Divergent RNA Affinities of 3′-Fluoro Hexitol Nucleic Acid (FHNA and Ara-FHNA) Modified Oligonucleotides Synthesis and Antisense Properties of Fluoro Cyclohexenyl Nucleic Acid (F-CeNA), a Nuclease Stable Mimic of 2′-Fluoro RNA Structural basis for specific inhibition of Autotaxin by a DNA aptamer Therapeutic aptamers: developmental potential as anticancer drugs Efficient reverse transcription using locked nucleic acid nucleotides towards the evolution of nuclease resistant RNA aptamers Discovering aptamers by cell-SELEX against human soluble growth factors ectopically expressed on yeast cell surface sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In Vivo XNA marks the spot. What can we learn about the origins of life and the treatment of disease through artificial nucleic acids?RNA plasticity and selectivity applicable to therapeutics and novel biosensor development A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death Fit for the Eye: Aptamers in Ocular Disorders Blind tests of RNA nearest-neighbor energy prediction Acousto-microfluidics for screening of ssDNA aptamer.Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.Adhesion through single peptide aptamers.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy

P2860

Q22122129-73438725-881A-4A57-BC4B-024871FABE55 Q26738413-64A9A4BB-D339-404A-B50B-3915DEEB562C Q26744467-D2493411-F5E1-4911-9C82-15B519712C8E Q26747220-7836CC9E-1437-402E-932D-942014B62533 Q26747256-C1AC0432-19F1-4806-AF1D-55FCBF48CFBA Q26749412-C8FFE06E-A6DD-4E6B-974C-66AB618077DC Q26752642-F9775F35-67E0-41AF-AD26-1D04C10F6FCB Q26752799-ED4DF98C-C575-4374-AABF-B7B86CE0AA4F Q26766832-97F7789C-A9B6-447A-BEA9-9909DEA72D17 Q26772092-184636C4-B169-4AE6-91F4-1B00DCC58120 Q26776229-7E8FA42F-EC02-4FE1-951F-2EC4E7C6272E Q26782794-EBA90E6B-71BA-478C-B59C-1BCC4B8B5004 Q26824321-B8EA1CD4-551E-44F2-A918-BEBFAB7F8ABD Q26829798-5114E2F4-F30F-4F0E-98B3-46654153A306 Q26996166-B36DECD2-F4E5-49B9-806C-C5251919AB41 Q27001612-83DA9D78-E3B2-4502-BD81-9F9FB1979D96 Q27002403-33CC8CC5-387F-4D03-BAD6-6E299F438330 Q27014527-E835868F-255B-406C-8175-55688318795F Q27023295-CF0A0DE2-7388-410A-8826-D248F1E4FA81 Q27025832-4FAD083C-F797-4ECC-B655-057EFAB13154 Q27490421-0D6590CA-4960-489E-84A9-BF402654B44A Q27658166-CAEA4080-B073-4F95-AE2E-1AB6B3CC0D45 Q27663735-38675EA9-AD48-4038-993A-DCA88F50CACB Q27664845-0544CEAF-58E4-43E7-B186-41AABAF127D5 Q27673978-6E22469A-794D-48AA-BFB1-EFCEB189C024 Q27679106-6AF4A36A-CD83-47D3-9768-A7B07B99D973 Q27704519-0182883A-9664-411B-B433-2A095EA7A2A0 Q28085157-71322566-2A6C-4CA7-8B6B-94DB1BF0F4E8 Q28482539-E5667CB6-45EE-4631-BAF9-6B0053489F46 Q28541656-5ACA014E-42AF-497D-B357-07A4909EC214 Q28552652-B153809F-31AC-4D5E-B0E8-3CF5A14418D0 Q28706271-B23BB406-0F2D-41CD-BC84-56290D9C57CC Q28727743-D9E6E5F8-519E-48FB-98E8-9944B00332FC Q28740749-103B1A40-4CC9-4C62-9225-926E5FCE2E4B Q28828283-45FC1CED-3933-45F3-884D-BA28135A4C6E Q28828288-75F05706-D40E-4246-A44A-BB63B6111F36 Q30381725-C9F61097-DED3-462F-9604-D070B69A0A03 Q30434521-092C7739-2228-411B-AC93-F58BD913C8A2 Q30437104-F4D1F02C-E122-49B4-8352-87DD6C41290C Q30455612-E658C122-A182-44B1-8144-775454B423CD

P2860

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

http://www.wikidata.org/entity/Q34499843

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@ast

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@en

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@nl

type

label

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@ast

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@en

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@nl

prefLabel

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@ast

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@en

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@nl

P1433

Q34499843-CDB3221D-C41C-4213-97FA-4DAD18D186B8

P1476

Q34499843-CF088293-60B0-4BDA-8C9E-5C4BAA89A10B

P2093

Q34499843-08CC6734-0133-4110-A2C3-ACD4AD44B5DF

Q34499843-3116111D-48B7-4974-BAAF-0D6816BF1419

Q34499843-B95B7A2B-FD76-4D84-97CA-44AD48F9BC32

Q34499843-D63EB465-DECE-4FEB-9F64-8690BE728990

Q34499843-DCE81C87-DA6A-4CD4-9136-E2B57F870443

Q34499843-E7F92B44-31A2-47C4-80FD-CE47174F34B1

P2860

Q34499843-08E49694-A9B9-42BC-AF31-389FF52A845E

Q34499843-20D5223F-1A65-4EF5-85DA-6F42AE6BA367

Q34499843-2D1CA8CB-FA14-4996-A582-539589861A11

Q34499843-31C65FD4-BCFE-4121-B7D8-F8CAFE3CEF74

Q34499843-4BC37AF4-DBA3-417D-9C51-DB8E776F7740

Q34499843-5B4A2DD0-E354-4BB6-8543-FD98D4DE3747

Q34499843-73769334-E262-444D-813C-E6E8A27C2704

Q34499843-83EE69A7-296E-4938-88C8-38A40876C1E7

Q34499843-8B439828-DA7B-40D0-9724-8213FCAA3F56

Q34499843-AAAFA0DA-02D9-4773-9A1D-939AD76115F8

P2888

Q34499843-A848DA50-3896-4680-BB41-82CBBFA49F3A

P304

Q34499843-8D3F0F19-3E61-42F4-8893-794290B7DD5A

P31

Q34499843-EB2E1B5F-7AC2-4FCF-B5FA-53DB3020FB33

P356

Q34499843-0F678E5C-BEDE-4C6D-921A-BCFD210624DA

P433

Q34499843-01A6592C-E875-4895-A7A9-239D2714533B

P478

Q34499843-9E199689-33FD-471A-AFC5-2BF78462470B

P577

Q34499843-01151B38-3233-4954-8667-8060DB3AD3A3

P5875

Q34499843-8B63D80F-62BC-435B-9A6F-B4FD350EA15F

P698

Q34499843-4A67E0D2-DE1C-49D6-B4CF-42718DD530F1

P356

P1433

Nature Reviews Drug Discovery

P1476

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

@en

P2093

Anthony P Adamis

http://www.w3.org/2001/XMLSchema#string

David R Guyer

http://www.w3.org/2001/XMLSchema#string

David T Shima

http://www.w3.org/2001/XMLSchema#string

Emmett T Cunningham

http://www.w3.org/2001/XMLSchema#string

Eugene W M Ng

http://www.w3.org/2001/XMLSchema#string

Perry Calias

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.

Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.

Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.

Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment

Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1).

Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.

Alterations in Ca2+ cycling by lysoplasmenylcholine in adult rabbit ventricular myocytes.

Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy

P2888

P304

123-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD1955

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7260480

http://www.w3.org/2001/XMLSchema#string

P698

16518379

http://www.w3.org/2001/XMLSchema#string